TROV vs. ADAP, ARTV, BDTX, CRBU, CHRS, TCRX, CDTX, SLDB, EDIT, and CABA
Should you be buying Cardiff Oncology stock or one of its competitors? The main competitors of Cardiff Oncology include Adaptimmune Therapeutics (ADAP), Artiva Biotherapeutics (ARTV), Black Diamond Therapeutics (BDTX), Caribou Biosciences (CRBU), Coherus BioSciences (CHRS), TScan Therapeutics (TCRX), Cidara Therapeutics (CDTX), Solid Biosciences (SLDB), Editas Medicine (EDIT), and Cabaletta Bio (CABA). These companies are all part of the "medical" sector.
Cardiff Oncology vs.
Adaptimmune Therapeutics (NASDAQ:ADAP) and Cardiff Oncology (NASDAQ:TROV) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, institutional ownership, media sentiment, earnings, dividends, profitability, community ranking and risk.
Cardiff Oncology has lower revenue, but higher earnings than Adaptimmune Therapeutics. Adaptimmune Therapeutics is trading at a lower price-to-earnings ratio than Cardiff Oncology, indicating that it is currently the more affordable of the two stocks.
Adaptimmune Therapeutics has a net margin of -25.43% compared to Cardiff Oncology's net margin of -3,688.31%. Adaptimmune Therapeutics' return on equity of -74.15% beat Cardiff Oncology's return on equity.
31.4% of Adaptimmune Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Cardiff Oncology shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by insiders. Comparatively, 0.6% of Cardiff Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Adaptimmune Therapeutics has a beta of 2.24, suggesting that its stock price is 124% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.04, suggesting that its stock price is 4% more volatile than the S&P 500.
In the previous week, Adaptimmune Therapeutics had 5 more articles in the media than Cardiff Oncology. MarketBeat recorded 5 mentions for Adaptimmune Therapeutics and 0 mentions for Cardiff Oncology. Adaptimmune Therapeutics' average media sentiment score of 0.31 beat Cardiff Oncology's score of 0.00 indicating that Adaptimmune Therapeutics is being referred to more favorably in the media.
Cardiff Oncology received 85 more outperform votes than Adaptimmune Therapeutics when rated by MarketBeat users. Likewise, 73.09% of users gave Cardiff Oncology an outperform vote while only 63.02% of users gave Adaptimmune Therapeutics an outperform vote.
Adaptimmune Therapeutics presently has a consensus price target of $2.79, suggesting a potential upside of 357.72%. Given Adaptimmune Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Adaptimmune Therapeutics is more favorable than Cardiff Oncology.
Summary
Adaptimmune Therapeutics beats Cardiff Oncology on 13 of the 18 factors compared between the two stocks.
Get Cardiff Oncology News Delivered to You Automatically
Sign up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cardiff Oncology Competitors List
Related Companies and Tools
This page (NASDAQ:TROV) was last updated on 1/31/2025 by MarketBeat.com Staff
Free TROV Stock Alerts